Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)

Buti, MariaStepanova, TatjanaCelen, Mustafa K.Flisiak, RobertRyder, Stephen D.Streinu, Adrian CercelFlaherty, John F.Gaggar, AnuSuri, VithikaMo, ShuyuanSubramanian, ManiNurmukhametova, ElenaZoulim, FabienAndreone, PietroMarcellin, Patrick2023-09-212023-09-212017-10Buti, M. vd. (2017). ''Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)''. Hepatology, 66(Supplement 1), Special Issue, 488A-488A.0270-91391527-3350https://aasldpubs.onlinelibrary.wiley.com/loi/15273350http://hdl.handle.net/11452/33935Bu çalışma, 20-24, Ekim 2017 tarihlerinde Washington[Amerika]’da düzenlenen 68. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology & hepatologyEfficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)Meeting Abstract000412089801057488A488A66Supplement 1, Special IssueGastroenterology & hepatology